Sonia Elijah

It’s unequivocal: anaphylaxis was a known life-threatening adverse event, around the same time emergency use authorization was granted for the Pfizer-BioNTech COVID-19 vaccine. Yet, because it’s an “injectable vaccine” it somehow has gotten a free pass from all the drug regulators, no matter how much damning data accumulates, when a cough syrup or capsule on the other hand gets urgently recalled on the basis of a “a very rare risk of anaphylaxis.”

The 95% VE (vaccine efficacy) arises from the 8 confirmed Covid cases from the vaccinated group (from at least 7 days after Dose 2) compared to 162 from the placebo group. These two data points are essentially what Pfizer hang their hat on to prove their vaccine was a success.

For children to be described by Pfizer and BioNTech as ‘ongoing reservoirs of infection’ is offensive and epitomises the way they have been treated for the past two years-including being labelled as ‘super-spreaders.’ There have been several highly credible reports citing evidence, which state otherwise.